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1. Introduction
Enterohemorrhagic Escherichia coli (EHEC) is an impor-
tant zoonotic pathogen of humans, causing severe diarrhea 
(hemorrhagic colitis) and in a small percentage of cases, 
haemolytic-uremic syndrome (HUS). There are approxi-
mately 75,000 infections and 61 deaths/year in the USA [1]. 
Unfortunately, antibiotics increase the risk of HUS [2], and 
there are no current therapies for EHEC human infections 
other than general supportive measures [3]. EHEC serotype 
O157:H7 causes 85–95% of the cases of HUS in North Amer-
ica [4], and is also the leading cause of HUS in Europe [3].
Cattle are an important reservoir for E. coli O157:H7 
and many human infections are attributable to contact with 
contaminated meat or other sources, such as water, fruit or 
vegetables [4]. This organism can be found in 80% of some 
populations of live cattle [5], and 49% of beef carcasses [6], 
respectively. It does not appear to cause disease in adult cat-
tle, although it can cause diarrhea in neonates [7]. Serologic 
evidence suggests that most calves are exposed to E. coli 
O157:H7 [8]. The number of animals shedding the organ-
ism in their feces is usually higher in the summer months 
[9], which correlates with an increased incidence of human 
disease. Shedding is intermittent, but it is not known if the 
organism remains in the intestines of cattle during periods 
of time when it cannot be recovered from feces.
Since cattle and their products are associated with the 
majority of cases of E. coli O157:H7 infection in humans, 
they represent an attractive target for pre-slaughter inter-
vention as a means of reducing risk to humans. A number 
of approaches are being studied to reduce levels of the or-
ganism in cattle, including animal management practices 
such as chlorination of water [10], modifications to animal 
feed [11–13], the use of probiotics [14], and bacteriophage 
therapy [15]. Other vaccinations are also being investigated 
[16–18].
Proteins secreted by the type III system play a role in 
colonization of non-bovine hosts by E. coli O157:H7 [19], 
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Abstract
Cattle are an important reservoir of Escherichia coli O157:H7 leading to contamination of food and water, and subse-
quent human disease. This pathogen colonizes its hosts by producing several proteins such as Tir and EspA that are 
secreted by a type III secretion system. These proteins play a role in colonization of the intestine, suggesting that they 
might be useful targets for the development of a vaccine to reduce levels of this organism in cattle. Vaccination of cat-
tle with proteins secreted by E. coli O157:H7 significantly reduced the numbers of bacteria shed in feces, the numbers 
of animals that shed, and the duration of shedding in an experimental challenge model. Vaccination of cattle also sig-
nificantly (P=0.04) reduced the prevalence of E. coli O157:H7 in a clinical trial conducted in a typical feedlot setting. 
This strategy suggests it is possible to vaccinate cattle to decrease the level of E. coli O157:H7 shedding for the purpose 
of reducing the risk of human disease.
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and it is likely they are also required for colonization of the 
bovine intestine. One virulence determinant, Tir, is inte-
grated into the host cell membrane where it serves as the 
receptor for the bacterial outer membrane protein, intimin 
[19]. Tir-intimin binding is essential for bacterial adherence 
to host cells [19–21]. Proteins secreted via the type III path-
way, including Tir, EspA (which forms a linkage between 
bacterium and host cell), and EspB (which forms a pore in 
the host cell), are recognized by sera from convalescent in-
dividuals [22]. Dean-Nystrom et al. [20] demonstrated that 
intimin is required for the development of attaching-ef-
facing (A/E) lesions in neonatal calves, and that pedestals 
(protrusions beneath adherent bacteria mediated by type 
III effectors such as Tir) are present in infected ileal tissue. 
Baehler and Moxley [23], by inoculating explants prepared 
from 18-month-old slaughtered steers, demonstrated that 
adult bovine colonic and rectal epithelia are susceptible to 
E. coli O157:H7 induced A/E lesions. Subsequent studies, 
based on experimental inoculation of adult cattle, demon-
strated that expression of intimin [24] and Tir [25] are re-
quired for E. coli O157:H7 intestinal colonization. A study 
in swine demonstrated the potential for protection against 
A/E lesions and intestinal colonization by vaccination with 
intimin [26]. Collectively, these observations suggest that 
the type III secreted proteins are attractive targets for vac-
cine development.
2. Materials and methods
2.1. Bacterial strains and culture conditions
The E. coli O157:H7 strain used for the production of type 
III secreted proteins and experimental infection was orig-
inally obtained from Li et al. [22] and Tarr et al. [27] and 
the tir mutant was described by Li et al. [22]. Recombinant 
E. coli K12 strains used for the production of Tir and EspA 
were as described [22].
2.2. Preparation of type III secreted proteins and vaccine 
formulation
Supernatant proteins [containing type III secreted proteins 
(Esps and Tir)] were prepared from E. coli O157:H7 pre-
cisely as described [22], and formulated with the adjuvant 
VSA3 [28] such that the protein concentration was either 
25 or 100 μg/ml.
2.3. Vaccination and experimental infection of cattle
Calves and yearling cattle were obtained from farms in Sas-
katchewan, Canada and were housed at the University of 
Saskatchewan. They were fed a barley-based finishing ration 
with free choice roughage. All animals were screened prior 
to immunization for existing serum antibody titres against 
EHEC secreted proteins as well as shedding of E. coli O157:
H7. Animals which had existing titres or which were shed-
ding the organism at any point prior to experimental chal-
lenge were excluded from the study and were moved to sep-
arate housing to avoid cross-contamination. Cattle were 
immunized with 2 ml of each vaccine formulation deliv-
ered subcutaneously in the neck. In all experiments, a con-
trol vaccine group that received a formulation contain-
ing adjuvant only was included. Animals were challenged 2 
weeks following the last immunization with 108 CFU of E. 
coli O157:H7 by oral-gastric intubation and fecal shedding 
of the organism was monitored for 14 days. In the first ex-
periment described below, eight seronegative 6-month-old 
calves were vaccinated twice with 2 ml of the vaccine for-
mulation (100 μg/ml) by the subcutaneous route, while an 
equal number of age-matched calves received a placebo con-
taining adjuvant but no antigen. Bacteria were detected by 
direct plating of fecal samples which had been resuspended 
in saline on Sorbitol MacConkey agar supplemented with 
cefixime and tellurite [29]. A second vaccine trial was de-
signed in which three groups of yearling (adult) cattle were 
immunized as described above three times with 50 μg of su-
pernatant (n=13), 50 μg of secreted proteins from a tir mu-
tant [19] (ΔTir, n=10) or a placebo (n=25) on days 0, 21, and 
35. Fecal samples from yearling cattle were cultured after 
immunomagnetic enrichment [29 and 30] as well as direct 
plating. The immune response following immunization was 
measured using serum samples taken at the time of each 
vaccination by an enzyme-linked immunosorbent assay 
[31] and by Western blotting [22]. Differences in outcome 
variables between or among vaccine groups were assessed 
using the Wilcoxon Rank Sum Test or the Kruskal–Wal-
lis ANOVA, as appropriate. These differences were consid-
ered significant whenever P<0.05. This model typically re-
sults in measurable shedding of the organism for a period 
of approximately 60 days. All animal experiments were con-
ducted in accordance with the guidelines established by the 
Canadian Council for Animal Care.
2.4. Protection against natural exposure to E. coli O157:
H7
One hundred and ninety-two steers were blocked by weight, 
stratified by weight within block and assigned randomly to 
24 pens on 11 May 2002. The cattle were housed in outdoor 
dirt-floored pens with a stocking density of 28 square me-
ters of floor-space per animal. The finishing diet of 54.5% 
high moisture corn, 35% wet corn gluten feed, 5% corn si-
lage, 2.5% alfalfa hay, and 3% supplement was used for all 
animals. The treatments (vaccination, yes or no) were ran-
domly allocated to four pens within each of three weight 
blocks for a total of twelve repetitions per treatment. The 
treatments were initiated (treatment day 0) 9, 17, and 23 
days after cattle arrived in the feedyard for blocks 1, 2, 
and 3, respectively. The vaccine was the same as described 
above, consisting of secreted proteins of E. coli O157:H7, 
and was administered subcutaneously (50 μg/dose) to cat-
tle within assigned pens on treatment days 0, 21, and 42 of 
each block. Cattle within the control pens received an injec-
tion of adjuvant on the same schedule as vaccinated cattle. 
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Samples of rectal feces were collected for bacterial culture 
from cattle within each block on treatment days 0, 21, 42, 
63, 84, and the day of marketing (treatment days 106, 104, 
and 105 of blocks 1, 2, and 3, respectively).
Outcome measures were pen-level performance and the 
proportion of animals per pen culture-positive for E. coli 
O157:H7. Feedlot performance and E. coli O157:H7 culture 
outcomes were analyzed after arcsine transformation of the 
proportions accounting for block as a random effect and re-
peated sampling for E. coli O157:H7.
Fecal samples were cultured for E. coli O157:H7 as pre-
viously described [5] with modifications. Ten grams fecal 
samples were incubated 6 h in 90 ml Gram-negative (GN) 
broth containing 8 μg/ml vancomycin, 0.05 μg/ml cefix-
ime, and 10 μg/ml cefsulodin. One ml of this culture was 
subjected to O157 immunomagnetic separation (Dynal, 
Lake Success, NY), and 20 μl of the bead-bacteria mixture 
was spread onto sorbitol-MacConkey plates containing ce-
fixime (0.05 μg/ml) and potassium tellurite (2.5 μg/ml; 
CT-SMAC) and cultured overnight. Individual sorbitol-
nonfermenting colonies were subcultured for isolation on 
CT-SMAC plates, and an individual sorbitol-nonferment-
ing colony from each plate was inoculated onto both Mac-
Conkey and Fluorocult (EM Science, Gibbstown, NJ) agars. 
Isolates that fermented lactose but not sorbitol within 24 h 
and had a negative 4-methylumbelliferyl-β-  -glucuronide 
(MUG) reaction were streaked for isolation on blood agar 
plates. Following overnight incubation, one colony per iso-
late from a blood agar plate was tested for E. coli O157 and 
H7 antigens by latex agglutination (Remel, Lenexa, KS).
Isolates that were positive for O157 antigen by latex ag-
glutination (regardless of H7 results) were tested in a five 
primer-pair multiplex polymerase chain reaction (PCR) 
assay that detected genes for E. coli O157 (rfbEO157:H7), 
H7 (fliCh7), Shigatoxins 1 (stx1) and 2 (stx2), and intimin 
(eae). For PCR amplification, cells from an individual col-
ony on blood agar were transferred into a 1.5 ml Eppendorf 
tube containing 50 μl sterile nuclease-free water and incu-
bated at 100 °C for 6 min. The tube was then centrifuged 
at 2000 rpm for 2 min in a microfuge and the supernatant 
used as template. For each assay, template prepared from 
E. coli O157:H7 strain EDL933 (ATCC #43895) was used as 
a positive control, and one lacking any template was used 
as a negative control. The PCR was conducted in a 50 μl re-
action mixture containing 2 μl template DNA, 10 mM Tris–
HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl2, 200 μM of each 
dNTP (Promega, Madison WI), and 1.5 U Taq DNA poly-
merase (Promega). Oligonucleotide primers (Table 1) were 
used at the following concentrations: 0.5 μM for those tar-
geting the eae, stx1, stx2, and rfbEO157:H7 genes, and 0.2 μM 
for those targeting the fliCh7 gene. Samples were amplified 
in a PTC-200 DNA engine (MJ Research Inc., Incline Vil-
lage, NV) under the following cycling conditions. Condi-
tions included an initial denaturation step of 5 min at 94 °C, 
followed by 34 cycles with denaturing at 94 °C for 45 s, an-
nealing at 50 °C for 30 s, and extension at 72 °C for 90 s. 
The final cycle consisted of extension for 10 min at 72 °C, 
ramping to 50 °C at 0.1 °C/s, holding 50 °C for 5 min, ramp-
ing to 4 °C at 0.2 °C/s, and soaking at 4 °C. Samples were 
analyzed by standard agarose gel electrophoresis (10 μl per 
sample) on a 1.3% gel, stained with ethidium bromide, and 
then visualized under UV illumination. DNA molecular size 
standards (PCR marker, Promega, Madison WI) and posi-
tive and negative controls were included in every run.
3. Results
To test the vaccine potential of secreted proteins, superna-
tant proteins [containing type III secreted proteins (Esps 
and Tir)] were prepared from E. coli O157:H7, formulated 
at a dose of 100 ug/ml and used to vaccinate eight calves. 
A second group of calves which received a placebo vaccine 
was also included. The group that received the EHEC vac-
cine showed a 13-fold increase in specific antibody titre to 
type III secreted proteins after a single immunization, and 
after a booster vaccination on day 21, the EHEC vaccine 
group demonstrated a 45-fold increase in specific antibody 
titre while only one of the placebo vaccine group serocon-
verted (χ2, P=0.0002). On each of the post-challenge days,
Table 1. Oligonucleotide primers used in multiplex PCR to confirm identity of isolates as E. coli O157:H7
Primer           Oligonucleotide sequence (5′–3′)                     Product size (bp)                  Target                                  Reference
AE19  CAGGTCGTCGTGTCTGCTAAA  1087  eae  [33]
AE20 TCAGCGTGGTTGGATCAACCT
FLICH-7F  GCGCTGTCGAGTTCTATCGAGC  625  fliCh7  [34]
FLICH-7R  CAACGGTGACTTTATCGCCATTCC
Stx1F  TTCGCTCTGCAATAGGTA  555  stx1  [35]
Stx1R  TTCCCCAGTTCAATGTAAGAT
O157F  CGGACATCCATGTGATATGG  259  rfbEO157:H7 [36]
O157R  TTGCCTATGTACAGCTAATCC
Stx2F  GTGCCTGTTACTGGGTTTTTCTTC  118  stx2  [35]
Stx2R  AGGGGTCGATATCTCTGTCC
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fewer EHEC-vaccinated animals shed bacteria compared to 
the placebo group (Figure 1). Seven of eight placebo-immu-
nized animals shed the bacteria during the trial and four of 
those animals shed for four or more consecutive days. Five 
of eight EHEC vaccine-immunized animals shed the bac-
teria at some point during the trial, but only one shed for 
more than two consecutive days, indicating that coloniza-
tion was transient and significantly less than the placebo 
group. The total number of bacteria isolated from fecal 
samples was significantly lower among the EHEC-vacci-
nated group as compared to the placebo group (Wilcoxon 
Rank Sum Test, P=0.05), with the former having a median 
of 6.25 colony forming units (CFU) per gram of feces recov-
ered compared to a median value of 81.25 CFU/g for the 
latter.
No significant differences in anti-EHEC, anti-Tir or 
anti-EspA responses were observed between groups of six 
calves immunized with 50, 100, or 200 μg of supernatant, 
but all three were significantly higher than the placebo 
group on days 21 (boost) and 35 [25]. Thus, a second vac-
cine trial was conducted in which three groups of yearling 
cattle were immunized with supernatant prepared from 
the wild-type strain (n=13), from a tir mutant [19] (ΔTir, 
n=10) or a placebo (n=25) on days 0, 21, and 35, followed 
by oral challenge with E. coli O157:H7 on day 49. The group 
that received the ΔTir vaccine showed a response of similar 
magnitude against total secreted proteins as the group that 
received the vaccine prepared from the wild-type strain, 
but, as expected, a significantly reduced response to Tir 
(Wilcoxon Rank Sum Test, P=0.006) (Table 2). However, 
the former group did show an increase in anti-Tir antibody 
levels (Wilcoxon Rank Sum Test, P=0.009), indicating ei-
ther exposure to an organism producing an immunologi-
cally-related molecule or natural exposure to E. coli O157:
H7. This is further supported by the observation that there 
was an increase in the anti-Tir antibody titre in the placebo 
group on the day of challenge (Wilcoxon Rank Sum Test, 
P=0.002) but no difference between the placebo or ΔTir 
groups (P=0.37, Kruskal–Wallis ANOVA). The response to 
EspA, a type III secreted protein, was similar in both the 
EHEC and ΔTir vaccine groups (P=0.45, Kruskal–Wallis 
ANOVA) and was significantly higher than the placebo-im-
munized animals (P<0.0001).
The proteins secreted by the type III system were highly 
immunogenic in cattle (Figure 2). EspB, EspD and Tir were 
all reactive and after the second immunization on day 21, 
a significant response against lipopolysaccharide was also 
observed. The kinetics of the immune response in a vacci-
nated animal (Figure 2, bottom panels) show that anti-Tir 
antibodies were detectable following a single immuniza-
tion, as were antibodies against 43 and 100 kDa proteins. 
The latter proteins were produced by the wild-type strain as 
well as the sepB and tir mutants and the 100 kDa protein is 
probably EspP, a non-type III EHEC secreted protein.
After oral challenge with E. coli O157:H7 on day 49, 
each group was monitored daily for fecal shedding of the 
organism for 14 days. In this experiment, bacteria were cul-
tured after immunomagnetic enrichment [29, 30] rather 
than direct plating as yearling cattle shed less than calves in 
this infection model. On the day of challenge, two animals 
in the placebo group were culture-positive for E. coli O157:
H7 and were eliminated from the trial. The placebo-im-
munized animals shed the organism after challenge much 
more than those in the two EHEC vaccine groups (Figure 
3). Animals receiving the placebo shed the organism for a 
median of 4 days, significantly longer than the median of 0 
day by the other two vaccine groups (P=0.0002, Kruskal–
Wallis ANOVA). Significantly fewer bacteria were recovered 
from the EHEC and ΔTir vaccine groups (P=0.04, Kruskal–
Wallis ANOVA). From day 2 post-infection onwards, 78.3% 
of the placebo animals (18 of 23 animals) shed the organ-
Figure 1. Number of calves shedding E. coli O157:H7 on each day fol-
lowing experimental challenge. The strain used for infection [22–27] 
was grown to mid-exponential phase as described [22]. Bacteria were 
detected by direct plating of fecal samples that had been resuspended 
in saline on Sorbitol MacConkey agar supplemented with cefixime and 
tellurite [29]. Solid bars, placebo group; hatched bars, EHEC vaccine 
group. 
Table 2. Median serological response of yearling cattle to immunization with secreted proteins prepared from wild-type E. coli 
O157:H7 (EHEC), an isogenic tir mutant (ΔTir) or a placebo.
Group        N     Anti-EHEC                                                          Anti-Tir                                                                     Anti-EspA
                            Day 0                     Day 49                                  Day 0                          Day 49                                   Day 0                                Day 49
EHEC  13  10 (10–100)  6400 (3200–12800)  100 (10–200)  1600 (800–3200)  100 (10–200)  400 (200–1600)
ΔTir  10  10 (10–100)  6400 (3200–25600)  10 (10–200)  200 (100–800)  100 (10–200)  300 (100–1600)
Placebo  25  10 (10–200)  10 (10–200)  100 (10–200)  200 (10–400)  100 (10–200)  100 (10–200)
Titres are expressed as median values of the last positive dilution of sera [31]. Numbers in parentheses represent the 25th–75th percentile.
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ism for at least 1 day as compared to 15.4% of the EHEC 
(2 of 13, P=0.003) and 30% (3 of 10, P=0.008) of the ΔTir 
vaccinates.
To determine whether vaccination would have an ef-
fect on E. coli O157:H7 infection occurring from natural 
exposure, a clinical trial was conducted. Specifically, the 
trial evaluated the effect of vaccination on the proportion 
of feedlot steers shedding E. coli O157:H7 in their feces in 
typical feedlot conditions of exposure. Treatment groups 
did not differ in performance (viz. average daily gain, dry 
matter intake, gain to feed, marbling score, fat thickness, or 
yield grade).
The pre-treatment prevalence of animals shedding E. 
coli O157:H7 averaged 30%, and did not differ significantly 
between treatments (P=0.66). The average proportion of 
cattle shedding E. coli O157:H7 differed (P=0.04) over the 
five test-periods (treatment days 21, 42, 63, 84, and the day 
of marketing; 24, 10.9, 13.0, 5.7, and 21.4%, respectively); 
however, no interaction was observed between treatment 
and test-period (P=0.62). The average proportion of cat-
tle shedding E. coli O157:H7 in vaccine treated pens (8.8%) 
was significantly less (P=0.04) than in non-vaccinated pens 
of cattle (21.3%) (Figure 4). A total of 362 E. coli O157:H7 
isolates were obtained from the cattle in this clinical trial. 
By the five primer-pair multiplex PCR, all isolates were 
positive for the rfbE and fliCh7 genes; 315 isolates were also 
positive for the stx2 and eae genes, but negative for stx1; 42 
isolates were positive for all five genes.
4. Discussion
The data presented above demonstrate that virulence fac-
tors secreted by the type III system can be used as effec-
tive vaccine components for the reduction of colonization 
of cattle by E. coli O157:H7 in an experimental challenge 
model, and in a clinical trial testing under conditions of 
natural exposure within a feedlot setting. These proteins 
are major targets of the immune response in humans fol-
lowing infection [22], although calves do not usually mount 
a significant serological response against these proteins fol-
lowing natural exposure to the organism. However, cattle 
Figure 2. Immunoblot analysis of sera from vaccinated yearling cattle against EHEC secreted proteins. Each blot contains secreted proteins from 
wild-type E. coli O157:H7 (EHEC), type III secretion mutant (ΔSepB), tir mutant (ΔTir) and a purified glutathione-s-transferase:Tir fusion protein 
(GST-Tir). Proteins were separated by SDS-10% PAGE and stained with Coomassie blue (A, upper left panel) or transferred to nitrocellulose and 
probed with representative sera from animals which received three immunizations with each vaccine formulation (A). The lower four panels (B) 
were probed with sera from one representative animal which received the EHEC vaccine, taken on days 0, 21, 35 and 49 of the trial (prebleed, after 
initial immunization, after boost #1, after boost #2, respectively). 
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vaccinated with these proteins are primed and show an in-
crease in anti-EHEC and anti-Tir titres following oral chal-
lenge with the organism [25].
Tir is likely required for colonization of the bovine intes-
tine [25], and this is supported by the observation that a vac-
cine containing secreted proteins from a ΔTir E. coli O157:
H7 strain was not as efficacious as an identical formulation 
from an isogenic wild-type isolate. However, the former vac-
cine was significantly more efficacious than a placebo sug-
gesting that immunity against colonization is multifactorial 
in nature. This is supported by the Western blot analysis of 
the response to immunization in which several protein com-
ponents as well as lipopolysaccharide were recognized.
The clinical trial was conducted under conditions of 
natural exposure in an environment typical of feedyards in 
the Central US and Canada. The prevalence of E. coli O157:
H7 shedding observed among all of the cattle at the begin-
ning of the trial and among control group cattle throughout 
the trial was typical of that previously observed in both re-
search [32] and commercial feedyards [5]. During the trial, 
the prevalence of cattle shedding E. coli O157:H7 varied 
over time within both treatment groups.
Longitudinal studies have documented that within the 
same group of cattle the proportion of cattle shedding E. 
coli O157:H7 can vary greatly (1–80%) over the course of 
the feeding period [32]. In this study, even though preva-
lence of shedding varied by time period, vaccination re-
sulted in proportionately less shedding in the five test-pe-
riods compared to controls. Three doses of vaccine were 
administered during the clinical trial; however, it is not 
clear that all three doses were necessary for effect. The 
prevalence of shedding was observed to decrease following 
the first vaccination in the clinical trial. Also, no interaction 
was observed between treatments and test-periods suggest-
ing that the effect of vaccine on fecal shedding did not differ 
after the first vaccination. The issue is of practical impor-
tance since feedlot operators may be challenged to com-
ply with the need to repeatedly vaccinate cattle, and greater 
numbers of doses increase the cost of feedlot cattle produc-
tion. Therefore, the most efficient number of vaccine doses 
must be tested in additional studies. However, the results 
of the first vaccine trial in calves described above suggests 
that a schedule of two immunizations would be sufficient to 
significantly reduce the numbers of animals shedding the 
organism.
The prevalence of non-O157 serotypes in North Amer-
ica appears to be increasing and represents a significant 
portion of EHEC infections in other geographical loca-
tions. Since the type III secreted antigens are relatively 
conserved among non-O157 EHEC serotypes, this vaccine 
formulation might be broadly cross-protective, in contrast 
to formulations based upon the specific O157 LPS antigen. 
The vaccine described here is relatively simple and eco-
nomical to prepare, an essential requirement for any bo-
vine vaccine. In addition, it emphasizes the feasibility of 
vaccinating an animal reservoir to potentially decrease hu-
man infections.
Figure 3. Percentage of each group of yearling cattle shedding E. coli 
O157:H7 (A) and total number of bacteria recovered (B) on each day 
after experimental infection. Bacteria were detected in feces by plat-
ing on Sorbitol MacConkey agar supplemented with cefixime and tel-
lurite following immunomagnetic enrichment as described [29]. (A) 
Solid bars, placebo; hatched bars, EHEC vaccine; open bars, ΔTir vac-
cine. (B) Squares, placebo group; circles, EHEC vaccine; triangles, 
ΔTir vaccine. 
Figure 4. The proportion of cattle shedding E. coli O157:H7 within 
pens of vaccinated and unvaccinated cattle in conditions of natural ex-
posure. Arrows indicate the time of vaccination. Test-periods repre-
sent the day of sampling at 3 week intervals (treatment days 0, 21, 42, 
63, 84, and the day of marketing), with 0 representing sampling prior 
to the first vaccination. Triangles, unvaccinated controls; squares, vac-
cinated animals. 
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